Rambus Available For Sale Securities Debt Securities Current increased by 12.6% to $651.82M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 70.5%, from $382.20M to $651.82M. Over 5 years (FY 2020 to FY 2025), Available For Sale Securities Debt Securities Current shows an upward trend with a 9.2% CAGR.
An increase suggests higher liquidity and a conservative cash management strategy, while a decrease may indicate cash deployment for operations or acquisitions.
This represents the portion of a company's investment portfolio consisting of debt securities that are expected to be so...
Common among large-cap pharmaceutical firms maintaining significant cash reserves for R&D and M&A activities.
current_assets_available_for_sale_securities_debt_securi_87ec82| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $272.38M | $267.86M | $377.72M | $164.56M | $180.18M | $123.29M | $187.89M | $192.26M | $210.44M | $243.59M | $331.08M | $278.44M | $308.31M | $318.72M | $382.02M | $382.20M | $507.07M | $594.10M | $579.01M | $651.82M |
| QoQ Change | — | -1.7% | +41.0% | -56.4% | +9.5% | -31.6% | +52.4% | +2.3% | +9.5% | +15.8% | +35.9% | -15.9% | +10.7% | +3.4% | +19.9% | +0.0% | +32.7% | +17.2% | -2.5% | +12.6% |
| YoY Change | — | — | — | — | -33.9% | -54.0% | -50.3% | +16.8% | +16.8% | +97.6% | +76.2% | +44.8% | +46.5% | +30.8% | +15.4% | +37.3% | +64.5% | +86.4% | +51.6% | +70.5% |